Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials
Entrectinib, a TRK and ROS1 inhibitor that enters the brain, shrank tumours in more than half of patients with NTRK fusion-positive cancers of ten types and controlled brain metastases, leading to a tumour-agnostic approval alongside larotrectinib.
Overview
Integrated analysis of 54 adults with NTRK fusion-positive solid tumours from the ALKA-372-001, STARTRK-1 and STARTRK-2 trials treated with entrectinib.
Objective response was 57 percent with a median duration of response of 10 months and intracranial response in half of the patients with brain metastases; toxicity included weight gain, dizziness and dysgeusia.
- Objective response 57 percent; median duration of response 10 months.
- Intracranial response in 50 percent of patients with brain metastases.
Entrectinib is an approved tumour-agnostic TRK inhibitor with an advantage in patients with brain metastases, and it is also approved for ROS1-positive lung cancer.
- Small pooled population; median progression-free survival 11 months.
Similar pages
not linked directly; found by shared links- Key paperEntrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three trials
Shares Entrectinib, The Lancet Oncology.
- TrialBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme
Shares NTRK fusion-positive non-small-cell lung cancer, Entrectinib.
- TargetROS1
Shares NTRK fusion-positive non-small-cell lung cancer, Entrectinib.
- TargetNTRK
Shares NTRK fusion-positive non-small-cell lung cancer, Entrectinib.
- TermGene fusion
Shares NTRK fusion-positive non-small-cell lung cancer, Entrectinib.